2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

The return of spontaneous circulation (ROSC) marks the transition from acute cardiopulmonary resuscitation to the complex, multidisciplinary phase of post-cardiac arrest care. Survivors of cardiac arrest suffer from post-cardiac arrest syndrome (PCAS), a multifaceted pathophysiological state characterized by post-arrest brain injury, myocardial stunning, systemic ischemia-reperfusion response, and persistent precipitating pathology. Emergency medicine pharmacists play an essential role in optimizing oxygenation, hemodynamics, Targeted Temperature Management (TTM), shivering suppression, and navigating hypothermia-induced pharmacokinetic changes.

---

Initial Cardiopulmonary and Hemodynamic Optimization

Following ROSC, immediate management focuses on systematic physiological stabilization to prevent secondary neurological and myocardial injury:

1. Oxygenation Targets: Avoiding Hypoxia and Hyperoxia

• Target $SpO_2$: 90% to 98% in the 2025 AHA guidelines (PaO2 roughly 60 to 105 mmHg). The 2025 ESICM guideline uses a slightly higher floor of 94% to 98%, which is sensible when pulse oximetry may overestimate saturation, such as in patients with darker skin.
• Danger of Hypoxia ($SpO_2 < 92\%$ or $PaO_2 < 60\text{ mmHg}$): Precipitates recurrent cardiac arrest and exacerbates ischemic neuronal apoptosis.
• Danger of Hyperoxia ($PaO_2 > 300\text{ mmHg}$): Exposing ischemic-reperfused brain tissue to supraphysiologic oxygen tensions generates cytotoxic reactive oxygen species (ROS), accelerates membrane lipid peroxidation, triggers cerebral arteriolar vasoconstriction, and directly worsens post-resuscitation functional recovery.

2. Ventilation Targets: Normocarbia

• Target $PaCO_2$: 35 to 45 mmHg (or end-tidal $CO_2\text{ }35\text{ to }40\text{ mmHg}$).
• Danger of Hypocapnia ($PaCO_2 < 35\text{ mmHg}$): Hyperventilation causes marked cerebral vasoconstriction, drastically reducing cerebral blood flow and inducing secondary cerebral ischemia.
• Danger of Hypercapnia ($PaCO_2 > 45\text{ mmHg}$): Induces cerebral vasodilation, increasing intracranial pressure (ICP) in the setting of post-ischemic cerebral edema, while worsening respiratory acidosis.

3. Hemodynamic Targets

• Blood Pressure Goals: Maintain MAP $\ge 65\text{ mmHg}$ (frequently targeting $\ge 65\text{ to }80\text{ mmHg}$ in patients with chronic hypertension to preserve cerebral perfusion pressure given impaired autoregulation) and systolic blood pressure $\ge 90\text{ mmHg}$.
• First-Line Vasopressor: Norepinephrine continuous IV infusion ($0.05\text{ to }0.5\text{ mcg/kg/min}$). Norepinephrine provides potent alpha-1 vasoconstriction to restore perfusion pressure along with modest beta-1 support.
• Post-Arrest Myocardial Dysfunction: Reversible ischemic myocardial stunning occurs in $>50\%$ of post-ROSC patients. If low cardiac output or persistent shock persists despite norepinephrine, add dobutamine ($2.5\text{ to }10\text{ mcg/kg/min}$) or substitute/add epinephrine ($0.05\text{ to }0.3\text{ mcg/kg/min}$).

4. Emergent Coronary Angiography

Immediate emergent cardiac catheterization is indicated for all post-ROSC adult patients who demonstrate ST-segment elevation myocardial infarction (STEMI) on their post-resuscitation 12-lead ECG, or those with refractory cardiogenic shock without an obvious non-cardiac cause, regardless of whether the patient is comatose.

---

Targeted Temperature Management (TTM): Evidence & Protocols

Targeted Temperature Management remains the cornerstone of neuroprotection for comatose adult patients with ROSC following cardiac arrest.

Candidate Selection & Temperature Target Selection

• Indications: All comatose adults (failing to follow verbal commands) after cardiac arrest, regardless of initial rhythm (shockable or non-shockable) or arrest location (OHCA or IHCA).
• Target Temperature Range: The 2025 AHA guidelines recommend deliberate temperature control with a target between 32°C and 37.5°C (Class 1). They no longer require the older 32°C–36°C range, reflecting the TTM-2 result that hypothermia offered no benefit over controlled normothermia. Prehospital cooling with cold IV fluids is not recommended.

Key Clinical Evidence (TTM-1 and TTM-2 Trials)

• TTM-1 Trial (2013): Compared hypothermia at 33°C versus 36°C in 950 OHCA patients and found no significant difference in all-cause mortality or neurological outcome at 6 months.
• TTM-2 Trial (2021): Compared hypothermia at 33°C versus targeted normothermia (early treatment of body temperature $\ge 37.8°\text{C}$ using surface/intravascular cooling devices) in 1,900 OHCA patients. The trial found no difference in 6-month mortality (50% vs. 48%) or functional disability. However, the trial strictly mandated active feedback cooling devices to prevent fever in the normothermia arm.
• Core Consensus: Fever ($>37.8°\text{C}$) is neurotoxic. Post-cardiac arrest hyperthermia drives cerebral metabolic rate, elevates ICP, accelerates apoptosis, and independently worsens mortality. Whether 33°C, 36°C, or 37.5°C is targeted, strict active temperature control must be maintained.

Protocol Duration and Rewarming Phase

• Maintenance Phase: The 2025 AHA guidelines suggest maintaining temperature control for at least 36 hours (Class 2a), using closed-loop feedback surface pads or intravascular cooling catheters with continuous core temperature monitoring (esophageal or bladder probe).
• Controlled Rewarming Phase: Rewarm slowly and precisely at a controlled rate of 0.25°C to 0.5°C per hour. Rapid rewarming triggers severe rebound intracranial hypertension, peripheral vasodilation with profound shock, and fatal hyperkalemia.
• Fever Prevention: Fever worsens brain injury. The 2021 ERC-ESICM guideline advised preventing fever ($>37.7°\text{C}$) for at least 72 hours, and the 2025 ESICM update recommends active fever prevention for 36 to 72 hours in patients who remain comatose.

---

Stepwise Shivering Management Protocol

Shivering is the body's primary homeostatic response to cold, initiated when preoptic hypothalamic thermal sensors detect core temperatures below the shivering threshold (~36.5°C). Shivering increases metabolic rate and whole-body oxygen consumption by 200% to 500%, increases carbon dioxide production, and elevates intracranial pressure, completely abolishing the neuroprotective benefits of TTM.

Bedside Shivering Assessment Scale (BSAS)

• 0 (None): No shivering detected on palpation.
• 1 (Mild): Shivering localized to neck or thorax; visible only on palpation.
• 2 (Moderate): Visible muscle tremor of extremities, pectoralis, or jaw.
• 3 (Severe): Generalized, vigorous muscle shaking involving entire body.

Multimodal Stepwise Shivering Algorithm

Loading diagram...

• Tier 1 (Non-Pharmacologic & Non-Sedating Baseline):
  • Surface Counter-Warming: Wrap hands, feet, and distal extremities in warm socks, gloves, or convective warm-air blankets. Tricking cutaneous thermoreceptors reduces hypothalamic afferent shivering triggers without altering core cooling.
  • Acetaminophen: 1 g IV or enteral every 6 hours scheduled.
  • Magnesium Sulfate: IV infusion targeting a serum magnesium level of 3.0 to 4.0 mg/dL (1.2 to 1.6 mmol/L). Magnesium acts centrally to lower the shivering threshold and promotes peripheral vasodilation.
• Tier 2 (Centrally Acting / Light Sedatives):
  • Buspirone: 30 mg enterally every 8 hours. A $5\text{-HT}_{1A}$ partial agonist that synergistically lowers the shivering threshold without sedation or respiratory depression.
  • Dexmedetomidine: Continuous IV infusion at 0.2 to 1.5 mcg/kg/hour. An alpha-2 adrenergic agonist that lowers the shivering threshold; monitor for dose-dependent bradycardia and hypotension.
• Tier 3 (Opioids):
  • Fentanyl: Continuous infusion 25 to 100 mcg/hour.
  • Meperidine: 25 to 50 mg IV push or continuous infusion. Meperidine uniquely lowers the shivering threshold through kappa-opioid and alpha-2 agonism. Safety Warning: Its neurotoxic metabolite, normeperidine, accumulates in renal impairment, lowering the seizure threshold.
• Tier 4 (Neuromuscular Blockade - NMB):
  • Cisatracurium ($1\text{ to }3\text{ mcg/kg/min}$) or Rocuronium ($0.3\text{ to }0.6\text{ mg/kg/hour}$) continuous infusion or boluses. Reserved exclusively for refractory shivering.
  • MANDATORY Requirement: Patients receiving paralytics must undergo continuous electroencephalography (cEEG) because neuromuscular blockade masks the peripheral motor manifestations of status epilepticus!

---

Altered Pharmacokinetics and Electrolyte Shifts in Hypothermia

Pharmacokinetic Derangements

Moderate hypothermia (32°C to 34°C) profoundly alters drug absorption, distribution, metabolism, and excretion:

1. Hepatic Clearance: Hypothermia impairs cytochrome P450 enzyme activity (CYP3A4, CYP2D6, CYP2C19) by 7% to 11% per 1°C drop below 37°C. Clearance of sedatives (midazolam, propofol), opioids (fentanyl), and paralytics (rocuronium, vecuronium) is reduced by 25% to 50%, prolonging elimination half-lives and causing severe drug accumulation.
2. Renal Clearance: Decreased renal perfusion and cold diuresis delay clearance of renally eliminated drugs.

Electrolyte Dynamics: Cooling vs. Rewarming

---

Glycemic Management and Multimodal Neuroprognostication

Glycemic Targets

Hypothermia induces peripheral insulin resistance and inhibits pancreatic beta-cell insulin secretion, resulting in hyperglycemia. The recommended target is 140 to 180 mg/dL (7.8 to 10.0 mmol/L). Avoid tight glycemic control (80 to 110 mg/dL) due to high risk of severe hypoglycemia ($<70\text{ mg/dL}$), which exacerbates neuronal death in ischemic brain tissue.

Multimodal Neuroprognostication Timeline

Accurate neuroprognostication cannot be performed prematurely. Definitive neuroprognostication must be delayed until AT LEAST 72 hours after return to normothermia (typically 5 to 7 days post-cardiac arrest):

• Confounders: Hypothermia and impaired drug clearance prolong the effects of sedatives, analgesics, and neuromuscular blockers. Neurological examination before 72 hours post-rewarming is fundamentally unreliable.
• Multimodal Evaluation Components:
  1. Clinical Exam: Bilaterally absent pupillary and corneal reflexes at $\ge 72\text{ hours}$ post-rewarming.
  2. Somatosensory Evoked Potentials (SSEP): Bilateral absence of the N20 cortical potential wave.
  3. Biomarkers: Marked, persistent elevations of serum neuron-specific enolase (NSE).
  4. Continuous EEG: Presence of highly malignant patterns (burst suppression, generalized suppression, non-reactive background, unreactive status epilepticus).
  5. Neuroimaging: Diffuse brain edema with loss of gray-white matter differentiation on head CT (decreased gray-to-white ratio $<1.15$) or extensive diffusion restriction on brain MRI.